Coronary Stents: Breaking J&J's Lock on the Market

Despite increasing worldwide competition, the coronary stent market continues to be technology driven, as new devices allow interventional cardiologists to customize treatment for different kinds of lesions. In the US, J&J’s patent will be key to the evolution of the market, but overseas, competitors are making inroads, often with stents that address issues not satisfactorily addressed by J&J’s stent.

by Wendy Diller

In the year and a half since Johnson & Johnson received FDA approval for the first coronary stent for prevention of restenosis following balloon angioplasty, the market for the devices has grown from a mid-sized, hardly astounding business ($220 million in worldwide sales in 1994) to one that is expected to capture as much as $1 billion in worldwide revenues this year. Some leading interventional cardiologists are reporting that half of the procedures they do now involve coronary stents, up from 20% a year ago, and analysts project compounded annual growth of 30% through 1999

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight